LY333531 (hydrochloride)

LY333531 is an inhibitor of PKCbeta (IC50s = 4.7 and 5.9 nM for PKCbeta1 and PKCbeta2, respectively). It is selective for PKCbeta1 and PKCbeta2 over PKCalpha, -gamma, -delta, -epsilon, -zeta, and -eta (IC50s = 360, 300, 250, >100,000, and 52 nM, respectively). LY333531 also inhibits glycogen synthase kinase 3beta (GSK3beta, IC50 = 39.4 nM). It inhibits neutrophil extracellular trap (NET) formation induced by phorbol 12-myristate 13-acetate (PMA, Cay-10008014) in primary human neutrophils when used at a concentration of 1 µM. LY333531 increases the mechanical nociceptive threshold in a rat model of diabetic hyperalgesia induced by streptozotocin (STZ, Cay-13104).Formal Name: (9S)-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione, monohydrochloride. CAS Number: 169939-93-9. Synonyms: Ruboxistaurin. Molecular Formula: C28H28N4O3 . HCl. Formula Weight: 505.0. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: :, :, DMSO: 10 mg/ml. SMILES: O=C(N1)C(C2=CN(CC[C@H]3CN(C)C)C4=C2C=CC=C4)=C(C5=CN(CCO3)C6=C5C=CC=C6)C1=O.Cl. InChi Code: InChI=1S/C28H28N4O3.ClH/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24,/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34),1H/t18-,/m0./s1. InChi Key: NYQIEYDJYFVLPO-FERBBOLQSA-N.